Intent-to treat population (n) | 138 | 132 | 127 |
WOMAC Index | | | |
Mean (SD) change in pain score | −19.4 (21.2) | −20.7 (22.7) | −12.4 (20.8) |
LS mean (SE) change | −18.2 (2.0)* | −20.3 (2.1)* | −9.9 (2.1) |
95% CI | −22.1 to −14.3 | −24.3 to −16.2 | −13.9 to −5.8 |
p Value, comparison with placebo | 0.0041 | 0.0004 | |
Mean (SD) change in physical function score | −16.0 (20.3) | −18.1 (22.5) | −12.3 (19.2) |
LS mean (SE) change | −14.6 (1.8) | −16.6 (1.8)* | −10.2 (1.8) |
95% confidence interval | −18.1 to −11.0 | −20.2 to −13.0 | −13.8 to −6.6 |
p Value, comparison with placebo | 0.08 | 0.01 | |
PGA of response at end of study | | | |
None (0), n (%) | 35 (25.4) | 34 (25.8) | 51 (40.2) |
Poor (1), n (%) | 16 (11.6) | 23 (17.4) | 20 (15.7) |
Fair (2), n (%) | 23 (16.7) | 24 (18.2) | 21 (16.5) |
Good (3), n (%) | 48 (34.8) | 37 (28.0) | 30 (23.6) |
Excellent (4), n (%) | 16 (11.6) | 14 (10.6) | 5 (3.9) |
Mean (SD) score | 2.2 (1.3) | 1.9 (1.3) | 1.5 (1.3) |
LS mean (SE) score | 1.8 (0.1)* | 1.7 (0.1)* | 1.3 (0.1) |
95% CI | 1.6 to 2.1 | 1.5 to 1.9 | 1.1 to 1.5 |
p Value, comparison with placebo | <0.01 | 0.02 | |